BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22294578)

  • 1. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
    Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
    PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biotech production facility contamination case study--minute mouse virus.
    Skrine J
    PDA J Pharm Sci Technol; 2011; 65(6):599-611. PubMed ID: 22294582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current testing methods and challenges for detection of adventitious viruses.
    Khan AS
    PDA J Pharm Sci Technol; 2011; 65(6):627-33. PubMed ID: 22294589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadening our expectations for viral safety risk mitigation.
    Kljavin IJ
    PDA J Pharm Sci Technol; 2011; 65(6):645-53. PubMed ID: 22294591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections.
    Eltermann J
    PDA J Pharm Sci Technol; 2011; 65(6):694-7. PubMed ID: 22294603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA post-approval expectations for adventitious virus contamination prevention.
    Friedman RL
    PDA J Pharm Sci Technol; 2011; 65(6):698-712. PubMed ID: 22294604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and remediation of a cell culture virus contamination.
    Jones N
    PDA J Pharm Sci Technol; 2011; 65(6):615. PubMed ID: 22294585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case study of apparent virus contamination in biopharmaceutical product at centocor.
    Hendricks LC; Vacante DA
    PDA J Pharm Sci Technol; 2011; 65(6):612-3. PubMed ID: 22294583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practicing safe cell culture: applied process designs for minimizing virus contamination risk.
    Kiss RD
    PDA J Pharm Sci Technol; 2011; 65(6):715-29. PubMed ID: 22294606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory approaches for control of viral contamination of vaccines.
    McClenahan S; Uhlenhaut C; Krause PR
    PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theory and practice of conventional adventitious virus testing.
    Gregersen JP
    PDA J Pharm Sci Technol; 2011; 65(6):634-44. PubMed ID: 22294590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral Safety of Plasma-derived Products.
    Farshid M
    PDA J Pharm Sci Technol; 2011; 65(6):737-53. PubMed ID: 22294608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contamination by porcine circovirus type 1: findings, investigations, and learnings.
    PiƩrard I
    PDA J Pharm Sci Technol; 2011; 65(6):614. PubMed ID: 22294584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to workshop: adventitious viruses in biologics--detection and mitigation strategies.
    Khan AS; Hughes P; Wiebe M
    PDA J Pharm Sci Technol; 2011; 65(6):544-6. PubMed ID: 22294575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of emerging technologies to detect adventitious agents.
    Onions D
    PDA J Pharm Sci Technol; 2011; 65(6):654-9. PubMed ID: 22294592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of DOP-PCR in Non-Specific Virus Detection.
    Uhlenhaut C; McClenahan S; Krause PR
    PDA J Pharm Sci Technol; 2011; 65(6):681-4. PubMed ID: 22294597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of quality by design in the control of adventitious viruses: gaps in current processes in the prevention of virus contaminants.
    Cherney B
    PDA J Pharm Sci Technol; 2011; 65(6):754-66. PubMed ID: 22294609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Risk Assessments in the Design of the Overall Viral Control Strategy Used during the Manufacture and Testing of Live Virus Vaccines.
    Pennathur S
    PDA J Pharm Sci Technol; 2011; 65(6):730-6. PubMed ID: 22294607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakout Session A: Elimination or Treatment of High-risk Raw Materials.
    Kiss R; Drews R
    PDA J Pharm Sci Technol; 2011; 65(6):767-77. PubMed ID: 22294610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.